NDAORALTABLET
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIQUAMAR (phenprocoumon) is an oral vitamin K antagonist anticoagulant approved in 1957 for prevention and treatment of thromboembolic disorders. It inhibits hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), reducing thrombosis risk in patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves. The drug is primarily used in European and Asian markets where it remains a standard-of-care option.
LOE Approaching
As a legacy anticoagulant facing LOE, LIQUAMAR teams are likely in maintenance/transition mode with reduced headcount, focused on maximizing existing market penetration rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Started Jul 2020
22,153 enrolled
Venous Thromboembolism
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Started Jun 2018
64,920 enrolled
Atrial Fibrillation
Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon
Started Oct 2015
40 enrolled
Atrial FibrillationLeft Atrial Thrombosis
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Started Sep 2013
2 enrolled
Malignant Melanoma, Neoplasms
Worked on LIQUAMAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.